life science investing Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
life science investing Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data
life science investing Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635
life science investing Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones
Element79 Gold Corp Announces Corporate Update and Strategic Leadership Changes With Focus On Accelerating Nevada Asset Development
